Journal of Clinical Medicine (Aug 2021)

Supervised Machine Learning Approach to Identify Early Predictors of Poor Outcome in Patients with COVID-19 Presenting to a Large Quaternary Care Hospital in New York City

  • Jason Zucker,
  • Angela Gomez-Simmonds,
  • Lawrence J. Purpura,
  • Sherif Shoucri,
  • Elijah LaSota,
  • Nicholas E. Morley,
  • Brit W. Sovic,
  • Marvin A. Castellon,
  • Deborah A. Theodore,
  • Logan L. Bartram,
  • Benjamin A. Miko,
  • Matthew L. Scherer,
  • Kathrine A. Meyers,
  • William C. Turner,
  • Maureen Kelly,
  • Martina Pavlicova,
  • Cale N. Basaraba,
  • Matthew R. Baldwin,
  • Daniel Brodie,
  • Kristin M. Burkart,
  • Joan Bathon,
  • Anne-Catrin Uhlemann,
  • Michael T. Yin,
  • Delivette Castor,
  • Magdalena E. Sobieszczyk

DOI
https://doi.org/10.3390/jcm10163523
Journal volume & issue
Vol. 10, no. 16
p. 3523

Abstract

Read online

Background: The progression of clinical manifestations in patients with coronavirus disease 2019 (COVID-19) highlights the need to account for symptom duration at the time of hospital presentation in decision-making algorithms. Methods: We performed a nested case–control analysis of 4103 adult patients with COVID-19 and at least 28 days of follow-up who presented to a New York City medical center. Multivariable logistic regression and classification and regression tree (CART) analysis were used to identify predictors of poor outcome. Results: Patients presenting to the hospital earlier in their disease course were older, had more comorbidities, and a greater proportion decompensated (8 days, 26%). The first recorded oxygen delivery method was the most important predictor of decompensation overall in CART analysis. In patients with symptoms for 8 days, requiring at least non-rebreather, age ≥ 63 years, and neutrophil/lymphocyte ratio ≥ 5.1; requiring at least non-rebreather, IL-6 ≥ 24.7 pg/mL, and D-dimer ≥ 2.4 µg/mL; and IL-6 ≥ 64.3 pg/mL, requiring non-rebreather, and CRP ≥ 152.5 mg/mL in predictive models were independently associated with poor outcome, respectively. Conclusion: Symptom duration in tandem with initial clinical and laboratory markers can be used to identify patients with COVID-19 at increased risk for poor outcomes.

Keywords